XALATAN Drug Patent Profile

When do Xalatan patents expire, and what generic alternatives are available?

Xalatan is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in XALATAN is latanoprost. There are twenty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xalatan

A generic version of XALATAN was approved as latanoprost by AMRING PHARMS on March 22^nd, 2011.

Summary for XALATAN

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XALATAN

US Patents and Regulatory Information for XALATAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	AT	RX	Yes	Yes

International Patents for XALATAN

See the table below for patents covering XALATAN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	560189
Canada	1208560	UTILISATION DES EICOSANOIDES ET DE LEURS DERIVES POUR LE TRAITEMENT DE L'HYPERTENSION OCULAIRE ET DU GLAUCOME (USE OF EICOSANOIDS AND THEIR DERIVATIVES FOR TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA)
Germany	3369068
Denmark	195083
European Patent Office	0093380	USE OF EICOSANOIDS AND THEIR DERIVATIVES FOR TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
Japan	H0468288
Japan	S591418	EICOSANOID AND DERIVATIVES FOR TREATING INTRAOCULAR ACCENTUATION AND GLAUCOMA

Supplementary Protection Certificates for XALATAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3461484	21C1024	France		PRODUCT NAME: ASSOCIATION DE NETARSUDIL OU L'UN DE SES SELS ET DE LATANOPROST; REGISTRATION NO/DATE: EU/1/20/1502 20210108
0364417	97C0111	Belgium		PRODUCT NAME: LATANOPROSTUM; NAT. REGISTRATION NO/DATE: 277 IS 271 F 13 19970617; FIRST REGISTRATION: SE 12716 1996071
3461484	SPC/GB21/033	United Kingdom		PRODUCT NAME: A COMBINATION OF LATANOPROST AND NETARSUDIL; REGISTERED: UK EU/1/20/1502(FOR NI) 20210107; UK PLGB 16053/0034 20210107
0364417	SPC/GB97/014	United Kingdom		PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
0364417	61/1997	Austria		PRODUCT NAME: LATANOPROST UND SEINE THERAPEUTISCH AKTIVEN UND PHYSIOLOGISCH ANNEHMBAREN DERIVATE; NAT. REGISTRATION NO/DATE: 1-22019 19970627; FIRST REGISTRATION: SE 12716 19960718
3461484	132021000000068	Italy		PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108
0364417	9690031-1	Sweden		PRODUCT NAME: LATANOPROST

Last updated: February 3, 2026

What is XALATAN and Its Market Position?

XALATAN (generic name: latanoprost) is a prostaglandin analogue used primarily to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Approved by the FDA in 1996, it is manufactured mainly by Pfizer, although generic versions have entered the market. XALATAN remains one of the most prescribed drugs for glaucoma management, with a significant share in the global ophthalmology market.

How Does XALATAN Perform in Market Fundamentals?

Market Size and Growth

The global glaucoma drugs market was valued at approximately USD 4.8 billion in 2021. It projected to grow at a compound annual growth rate (CAGR) of 5% through 2028, driven by aging populations, increased screening, and rising awareness of eye health.

XALATAN holds an estimated 45% share of the prostaglandin analogue segment, translating to roughly USD 2.16 billion in 2021. Its market dominance stems from efficacy, safety profile, and longstanding prescriber trust.

Competitive Landscape

• Generics: Since patent expiration in 2018, generic versions by Amneal, Sandoz, and others have reduced XALATAN's pricing but maintained volume share.
• Innovators: Pfizer's original formulation faces competition from other prostaglandin analogues like Travatan (travoprost), Taflotan (tafluprost), and Latisse (bimatoprost), mainly in differentiated indications.

Pricing and Revenue Trends

• Brand price: Original branded XALATAN sales per unit averaged USD 70-80 prior to generic entry.
• Generic impact: Prices declined by approximately 40% post-2018. The shift to generics resulted in revenue declines for Pfizer but increased volume sales globally.

Regulatory and Patent Landscape

• Pfizer held a method-of-use patent that expired in 2018, opening the market for generics.
• Patent disputes in certain regions delayed generic penetration, but the trend is towards increased commoditization.

What Are the Investment Considerations and Fundamentals?

Revenue and Profitability Outlook

• The original brand's revenue has declined from peak levels (~USD 1.2 billion/year) pre-2018 to an estimated USD 600-700 million in 2022.
• Generics are driving growth in volume, although at lower margins. Profitability is now concentrated in generic manufacturers, with Pfizer's revenues primarily derived from licensing and supply agreements.

R&D and Pipeline Status

• Pfizer's pipeline includes newer glaucoma treatments with better efficacy or delivery mechanisms, such as sustained-release implants.
• No current pipeline projects for XALATAN itself, indicating a potential decline in innovation related to the molecule.

Regulatory and Market Entry Barriers

• Entry barriers for generics: patent litigation, regulatory approval processes.
• For branded drugs, barriers include clinical trial requirements, high R&D costs.

Key Drivers and Risks

• Drivers: aging populations, increasing glaucoma prevalence, favorable long-term efficacy of prostaglandin analogues.
• Risks: pricing pressure from generics, competition from alternative therapies, patent challenges, and potential shifts in treatment guidelines.

Valuation Metrics

• Market Cap of Pfizer (2022): USD 221 billion.
• XALATAN's contribution: Approximately USD 600-700 million in revenues, representing around 0.3% of Pfizer's overall sales.
• Future outlook: As patent exclusivity diminishes, revenue contribution from XALATAN will decline unless innovative formulations or combinations emerge.

What Strategic Moves Are Evident in the XALATAN Space?

• Industry players invest in combination eye drops (e.g., timolol + latanoprost) to prolong product lifecycle.
• Development of sustained-release implants aims to improve adherence and reduce treatment burden.
• Companies explore gene therapy approaches for glaucoma, which could disrupt current prostaglandin analogue-based treatments.

How Does XALATAN Compare With Alternatives?

Aspect	XALATAN	Travatan	Taflotan
Approval Year	1996	2000	2012
Market Share (Segment)	45% of prostaglandin segment	~20%	Niche, emerging
Efficacy	Comparable among prostaglandins	Slightly lower, alternative formulations	Similar
Cost (Generic)	USD 10-15 (per bottle)	USD 10-15 (per bottle)	USD 15-20 (per bottle)

Generic versions have reduced price disparity, increasing affordability but pressuring margins for original manufacturers.

Key Investment and Business Insights

• Short-term: Revenue decline for Pfizer due to generic competition, but volume increases benefit other manufacturers.
• Medium-term: Innovation in delivery systems and combination therapies could exert upward pressure.
• Long-term: Market potential remains driven by glaucoma prevalence, but existing drugs face obsolescence with emerging therapies.

What Are the Key Takeaways?

• XALATAN has sustained a leading position in glaucoma therapy but faces structural decline as patent protections expire.
• The market is consolidating around generics, offering lower-cost alternatives but reducing margins for original developers.
• Investment opportunities exist in companies advancing drug delivery or combined therapies.
• Pfizer’s revenue exposure to XALATAN is diminishing, with focus shifting toward higher-margin pipeline products and generics.
• The overall glaucoma drugs market remains attractive due to aging populations, but innovation is critical for long-term growth.

FAQs

1. What is the main driver behind XALATAN’s market decline?
Patent expiration in 2018 allowed generic competitors to enter, leading to price reductions and volume-driven sales shifts.

2. Are there promising pipeline products related to XALATAN?
Current pipelines focus on sustained-release implants and combination therapies rather than new molecules similar to latanoprost.

3. How does the generics market affect profitability for original drug manufacturers?
Generics significantly decrease branded drug prices, often eroding profit margins and reducing revenue share for originators.

4. What is the future outlook for prostaglandin analogues in glaucoma treatment?
They remain effective, but new treatment modalities like gene therapy could alter the landscape within two decades.

5. Which regions show the highest growth potential for glaucoma drugs?
Emerging markets in Asia, Latin America, and Africa exhibit higher year-over-year growth due to increasing awareness and healthcare infrastructure improvements.

---

Sources

1. MarketWatch, "Global Glaucoma Drugs Market Size & Share Report," 2022.
2. Pfizer Annual Report 2022.
3. IQVIA, "Pharma Industry Data," 2022.
4. FDA, Approved Drugs Database, 2022.
5. Market Research Future, "Glaucoma Drugs Market Forecast," 2022.